Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Adocia (Euronext Paris : FR0011184241 - ADOC) announces today the initiation of a Phase Ib clinical trial evaluation for BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. This formulation uses Adocia's proprietary technology BioChaperone, which is believed to enable the acceleration of insulin absorption.
This is the first study to be initiated as part of the Adocia-Lilly partnership. The study aims to measure the effect of BioChaperone Lispro, injected at the time of a standardized meal, on post-meal glycemic control in type 1 diabetes patients and compare this effect to that of Humalog®(insulin lispro rDNA origin).
http://pipelinereview.com/index.php...-BioChaperone-Lispro-insulin-formulation.html
This is the first study to be initiated as part of the Adocia-Lilly partnership. The study aims to measure the effect of BioChaperone Lispro, injected at the time of a standardized meal, on post-meal glycemic control in type 1 diabetes patients and compare this effect to that of Humalog®(insulin lispro rDNA origin).
http://pipelinereview.com/index.php...-BioChaperone-Lispro-insulin-formulation.html